Anges MG, Inc.
Records under this name other than the patents Anges MG, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 2 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,012,749 | Methods for the production of hemagglutinating virus of Japan and adenovirus using cultured cells Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 7,897,751 | Pharmaceutical preparation Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,470,765 | Polypeptides and antibacterial or antiseptic use of same Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,695,219 | Polypeptide having antibacterial activity and angiogenesis-inducing activity and wound-healing drug containing said polypeptide Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,969,311 | Polypeptide Having Antibacterial Activity and Angiogenesis-Inducing Activity and Wound-Healing Drug Containing Said Polypeptide Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 9,376,470 | Polypeptide having angiogenesis-inducing activity and antibacterial activity, and use thereof for medical purposes Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,543,261 | DNA Vaccine Containing VEGF-Specific Epitope And/Or ANGIOPOIETIN-2-Specific Epitope Formerly held In force · High confidence | In force | High confidence | |
| US 9,913,886 | DNA vaccine containing specific epitope of apolipoprotein (a) Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,695,420 | DNA-Peptide Combination Vaccine Formerly held In force · High confidence | In force | High confidence | |
| US 7,790,692 | Hepatocyte growth factor nucleic acid sequence to enhance musculocutaneous flap survival Term ended Term ended Sep 2, 2026 · From the USPTO record | Term ended | Term ended Sep 2, 2026 | From the USPTO record |